Promising Nonalcoholic Steatohepatitis Therapies such as AZD2693, Saroglitazar Magnesium 4 mg, Semaglutide (SEMA), Cilofexor ...

Metabolic dysfunction-associated fatty liver disease (MAFLD) has become a growing global health concern, affecting millions ...

Meanwhile, resmetirom, a selective THR-β agonist, has received FDA breakthrough therapy designation due to its ability to reduce hepatic steatosis and inflammation. Additionally, dual PPARα/γ agonists ...